جستجوی استاد راهنمای دانشگاهی

• Nanotheranostics
• Quantitative Imaging
• MRI
• +۲ مورد دیگر

Holden H Wu is a Professor in the Department of Radiological Sciences at the University of California Los Angeles (UCLA) School of Medicine. His research focuses on advanced medical imaging techniques, particularly in quantitative MRI, artificial intelligence applications, and image-guided interventions. He leads the UCLA MRRL Wu Lab and has established himself as a leading researcher in free-breathing MRI techniques for body composition analysis and disease quantification. Dr. Wu's research interests span nanotheranostics, quantitative imaging, MRI technology development, artificial intelligence applications in medical imaging, and image-guided interventions. His work particularly emphasizes developing motion-robust techniques for abdominal and pediatric imaging, with applications in liver fat quantification, body composition analysis, and prostate cancer imaging. He has pioneered several free-breathing MRI techniques that have eliminated the need for breath-holding in patients, significantly improving clinical applicability, especially for pediatric populations and patients with limited breath-holding capacity. His recent publications demonstrate a strong focus on integrating deep learning with physics-based modeling to improve quantitative MRI techniques. Major trends in his research include the development of self-gated radial MRI techniques, motion-compensated imaging methods, and AI-powered analysis tools for medical imaging data. His work bridges engineering innovation with clinical applications, particularly in liver disease, metabolic disorders, and oncology. New Technologies for Real-Time MRI-Guided Robotic-Assisted Abdominal Interventions (NIH R01EB031934, 2022-2026) - Principal Investigator Quantitative MRI and Deep Learning Technologies for Classification of NAFLD (NIH U01EB031894, 2022-2027) - Principal Investigator Quantifying Body Composition and Liver Disease in Children using Free-Breathing MRI and MRE (NIH R01DK124417, 2020-2024) - Principal Investigator Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification (NIH R01CA248506, 2020-2025) - Co-Principal Investigator Dr. Wu has mentored numerous students and researchers through his active laboratory, focusing on training the next generation of biomedical imaging scientists. His research group, the UCLA MRRL Wu Lab, develops innovative imaging technologies with direct clinical translation potential. Current projects include developing real-time MRI-guided robotic interventions, advanced quantitative techniques for liver fat and fibrosis assessment, and AI-powered prostate cancer detection methods.

Adel Assadمشاهده پروفایل

پژوهشگر

• Nanotechnology
• Material Science
• Sustainable Energy
• +۳ مورد دیگر

Adel Assad is a Doctoral Candidate at Aalto University’s School of Chemical Engineering, specializing in the Nanochemistry and Nanoengineering group. His research focuses on sustainable materials, nanotechnology, and interdisciplinary applications combining materials engineering with arts and environmental science. He holds a Master's degree in Chemical, Biochemical, and Materials Engineering from Aalto University, with a minor in Fibre and Polymers Engineering. Adel’s work includes projects such as developing virtual laboratory safety training systems and part-time research on magnetic nanomaterials, electrospun fibres, and solar absorbers under Prof. Mady Elabhri. Research Interests: Adel’s research spans nanomaterial synthesis, plasmonic materials for energy applications, biomaterials for wound healing, and sustainable solar technologies. His projects often bridge fundamental science with practical solutions for environmental and energy challenges. Notable contributions include studies on polarizonic metasurfaces for camouflage and stealth, biosynthetic wound healing materials, and photochromic materials for smart surfaces. Articles and Trends: His publications highlight innovations in structural coloration, nanotheranostics for medical applications, and solar energy materials. Recent work explores ultraviolet absorbers using disordered metasurfaces and biohybrid nanofibers for therapeutic uses. These contributions underscore his focus on interdisciplinary nanotechnology for real-world impact. Awards: 2+2 Scholarship from Aalto University (2019). Grants/Support: Scholarship-funded doctoral position. Labs/Teams: Active member of the Nanochemistry and Nanoengineering group at Aalto University, collaborating on projects like colorful solar absorbers and sustainable material design.

Biswajit Dasمشاهده پروفایل

پژوهشگر

• Molecular Biology
• Cancer Biology
• Biochemistry
• +۳ مورد دیگر

Biswajit Das is a Researcher and Postdoctoral Fellow at the Department of Medical Biochemistry and Biophysics, Umeå University, affiliated with the Andrei Chabes group. His work focuses on molecular mechanisms underlying DNA damage responses, cancer biology, and cellular metabolism. He investigates dNTP homeostasis, replicative stress regulation, and the role of developmental signals in chromosomal stability during neurogenesis and pluripotency. Key research areas include tumor-associated fibrosis modulation, macrophage polarization in cancer immunotherapy, and nanomaterial-driven targeted drug delivery systems. Das has contributed to understanding how DNA damage responses interact with cellular metabolic pathways and how these interactions influence cancer progression and treatment efficacy. His publications span high-impact journals like Proceedings of the National Academy of Sciences (PNAS) and Nature Communications , addressing topics such as RRM2B deficiency, dNTP metabolism, and the development of novel therapeutic strategies for pancreatic and breast cancers. Das collaborates within the Andrei Chabes Lab, focusing on replicative stress and its implications for genetic stability. He has developed experimental models to study pancreatic cancer desmoplasia and employs advanced techniques in cell biology, biochemistry, and nanotechnology for translational research.

• Nanomedicine
• Drug Delivery
• Nanoparticles
• +۳ مورد دیگر

Silvia Pujals Riatós is a Researcher at the Core Facilities Unit of the Institute for Bioengineering of Catalonia (IBEC) in Barcelona, Spain, where she leverages advanced microscopy and nanomaterial characterization expertise to drive innovation in nanomedicine. Her dual role combines facility management with active research in developing next-generation nanocarriers for biomedical applications, particularly in drug delivery and cellular imaging. Her research spans nanomedicine, supramolecular chemistry, and super-resolution microscopy, with emphasis on designing light-activated drug delivery systems, quantifying nanoparticle behavior in biological environments, and engineering tumor-targeted nanotherapeutics. Key focus areas include supramolecular polymers, protein corona analysis, and real-time monitoring of nanocarrier dynamics in complex microenvironments like tumor-on-a-chip models. Her work bridges synthetic chemistry, materials science, and translational medicine to address challenges in cancer therapy and neurodegenerative diseases. Analysis of her 15 most recent publications (2021-2025) reveals three dominant trends: (1) Quantitative characterization of nanomaterial-biological interactions using cutting-edge microscopy techniques like DNA-PAINT and Glyco-PAINT, (2) Development of stimuli-responsive supramolecular systems with optimized stability-release profiles, and (3) Application of engineered nanocarriers in tumor models and cellular activation systems. Collaborations with the Albertazzi group and international teams demonstrate her integrative approach to solving biomedical challenges. As a core facility leader, Dr. Pujals provides critical infrastructure support for IBEC's research ecosystem, enabling high-impact studies through advanced nanomaterial analysis and super-resolution imaging services. Her facility work underpins projects ranging from fundamental protein interaction studies to preclinical cancer models, fostering interdisciplinary innovation across the institute.

Anthony J. Kimمشاهده پروفایل

استاد

• Nanomedicine
• Cancer Therapeutics
• Drug Delivery Systems
• +۳ مورد دیگر

Anthony J. Kim is a tenured Professor in the Department of Neurosurgery and Pharmacology at the University of Maryland School of Medicine. He directs the Nanotherapeutics Laboratory and co-directs the Translational Therapeutics Research Group (TTRG) , leading interdisciplinary research in nanomedicine for brain and breast cancers. His education includes a Ph.D. in Chemical and Biomolecular Engineering from the University of Pennsylvania and postdoctoral training at Johns Hopkins. Research focuses on overcoming biological barriers using engineered nanoparticles, with emphasis on glioblastoma and triple-negative breast cancer. His work integrates biophysical tools and DART nanoparticles to enhance drug delivery and therapeutic efficacy. Articles (2013–2025) demonstrate recurring themes: targeted nanotherapeutics , Fn14 receptor exploitation , and innovations in ultrasound-enhanced drug delivery . Key journals include ACS Nano , Science Advances , and Biomaterials . Honors & Grants: ATIP Award (2024), VA Merit Award (2022), NIH MERIT R37 (2018) Active grants: NIH R01 CA269995 (MPI), VA I01 BX005770 (PI), NIH R37 CA218617 (PI) He teaches clinical bioengineering courses at the University of Maryland Clark School of Engineering and mentors through UMGCCC programs.

Graeme F. Woodworthمشاهده پروفایل

استاد

• Brain Tumor Research
• Therapeutic Ultrasound
• Nanomedicine
• +۵ مورد دیگر

Graeme F. Woodworth, MD is the Howard M. Eisenberg, MD Distinguished Professor of Neurosurgery, Chair of the Department of Neurosurgery, and Director of the Brain Tumor Treatment and Research Center at the University of Maryland School of Medicine and University of Maryland Greenebaum Comprehensive Cancer Center. He leads a multidisciplinary team of neurosurgeons, radiologists, medical oncologists, and scientists focused on advancing brain tumor treatments through translational research and clinical innovation. Dr. Woodworth's educational background includes: Tufts University, BS, Chemistry, 1997 Johns Hopkins University School of Medicine, MD, 2005 Johns Hopkins Hospital, Intern, Surgery, 2006 Johns Hopkins Hospital, Resident, Neurosurgery, 2011 Johns Hopkins University School of Medicine, Fellow, Neuro-Oncology-NCI/Nanotechnology for Cancer Medicine Program, 2011 Weill Cornell Department of Neurological Surgery, Fellow, Cranial Neuro-Endoscopy, 2011 His research centers on three interconnected themes: Therapeutic Ultrasound development for blood-brain barrier disruption and drug delivery enhancement, Genetically-Engineered Models of glioma using transgenic rat systems, and Advanced Nanomedicine formulations for targeted brain tumor therapy. His work aims to transform glioblastoma from a uniformly fatal disease into a chronic condition through principles of maximal safe resection, intra-operative discovery, and targeted therapeutics for residual disease. Recent publications (2024-2025) demonstrate increasing integration of machine learning with focused ultrasound technology, expansion into brain metastasis treatment, and sophisticated nanoparticle engineering. Key trends include pivotal clinical trials (LIBERATE, LIMITLESS), closed-loop control systems for precision therapy, and multimodal approaches combining immunotherapy with blood-brain barrier modulation. Notable scientific awards include: Howard M. Eisenberg Distinguished Professorship (2023) Ferenc Jolesz Memorial Award (2022) Andrew J. Lockhart Memorial Prize (2019) Jorge Heller Outstanding Paper Award (2015) Research Scholar Award from American Cancer Society (2016) Multiple 'Top Docs' recognitions by Baltimore Magazine As department chair and center director, Dr. Woodworth oversees extensive research programs funded by NIH R01 grants, American Cancer Society awards, and Focused Ultrasound Foundation initiatives. His leadership drives multi-institutional collaborations including the ReSPOND consortium for glioblastoma research and clinical trials across 22 international sites. He mentors junior faculty and residents while directing the Translational Therapeutics Research Group's work on surgical outcomes registries for hydrocephalus, cerebrovascular disease, and spinal tumors. The Translational Therapeutics Research Group (TTRG) operates specialized facilities for in vivo brain tumor modeling, focused ultrasound applications, and nanomedicine characterization. Current initiatives include developing nestin-TV-A transgenic rat models for glioblastoma margin studies, optimizing MRI-guided focused ultrasound parameters for blood-brain barrier disruption, and engineering Fn14-targeted nanoparticles for precision drug delivery. The team collaborates closely with the University of Maryland Greenebaum Comprehensive Cancer Center's neuro-oncology program on first-in-human clinical trials.

• Neurosurgery
• Glioblastoma
• Therapeutic Ultrasound
• +۵ مورد دیگر

Graeme Woodworth is a Professor and Chair of the Department of Neurosurgery at the University of Maryland School of Medicine , where he also serves as Director of the Brain Tumor Treatment & Research Center at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). His work integrates clinical neurosurgery, translational research, and leadership in advancing therapies for brain tumors through innovative technologies like MRI-guided focused ultrasound and nanomedicine. He leads the Translational Therapeutics Research Group , bridging engineers, cancer biologists, and clinician-scientists to develop novel treatment paradigms. Education: Tufts University, BS, Chemistry, 1997 Johns Hopkins University School of Medicine, MD, 2005 Neurosurgery Residency, Johns Hopkins, 2011 Fellowships in Neuro-Oncology and Cranial Neuro-Endoscopy, 2011 Dr. Woodworth’s research focuses on therapeutic ultrasound to disrupt the blood-brain barrier (BBB) for enhanced drug delivery in glioblastoma, with clinical trials like LIBERATE and LIMITLESS under his leadership. His team’s work includes genetically engineered rat models for glioma studies, advanced nano-drug formulations targeting Fn14-positive tumors, and improving the safety and accuracy of neurosurgical interventions via outcomes registries. His publications highlight focused ultrasound , nanoparticle engineering , and translational neuro-oncology . Recent collaborations emphasize machine learning-based predictive models for tumor infiltration and recurrence, closed-loop ultrasound systems , and immunotherapy integration for CNS tumors. He has received numerous awards, including the Howard M. Eisenberg Distinguished Professorship (2023) and Elected Member of the American Society for Clinical Investigation (2025). His clinical expertise spans brain tumors, pituitary tumors, awake brain surgery, and spinal tumor resection.

Anna C. Samiaمشاهده پروفایل

استاد

• Analytical Chemistry
• Inorganic Chemistry
• Materials Science
• +۷ مورد دیگر

Anna C. Samia serves as the Rudolph and Susan Rense Professor of Chemistry and Chair of the Department of Chemistry at Case Western Reserve University, leading the Samia Research Group with active administrative and research responsibilities. Her academic foundation includes a BS from the University of the Philippines-Diliman (1996), a PhD from Georgia Institute of Technology (2002), and postdoctoral training at Case Western Reserve University (2002-2003), Argonne National Laboratory (2003-2005), and CWRU School of Medicine (2005-2010). Dr. Samia's research pioneers magneto-opto-electronic properties of intermetallic and metal oxide nanostructures through chemical design, targeting applications in nanotheranostics and environmental nanotechnology . Her group develops magnetic nanoparticle composites for MRI/MPI/hyperthermia, hybrid nanoparticles for environmental biosensing, and nanomaterial platforms for water treatment and agri-nanotechnology including targeted agrochemical delivery. Analysis of her 2013-2014 publications reveals an interdisciplinary focus on functional nanomaterials bridging medical diagnostics (e.g., MPI theranostics), antibacterial applications (iron oxide-carbon nanochains), and electrochemical sensing (Pt-Ag nanoboxes), demonstrating consistent innovation in nanomaterial synthesis for real-world implementation. Scientific Awards: No awards explicitly documented in source material As research group leader, Dr. Samia directs graduate student training and secures funding for nanotechnology projects spanning biomedical and environmental domains, though specific grant details and student names remain unlisted in available documentation. The Samia Research Group operates at the chemistry-engineering interface, maintaining specialized instrumentation for nanomaterial synthesis and characterization to advance applications in plant-microbe interactions, water purification, and medical imaging technologies.

Anu Airaksinenمشاهده پروفایل

استاد

• radiopharmaceutical chemistry
• PET radiochemistry
• image-assisted drug delivery
• +۳ مورد دیگر

Anu Airaksinen serves as a Professor at the PET Center of the University of Turku, Finland, with contact details including email anu.airaksinen@utu.fi and telephone numbers +358 29 450 2199 and +358 50 470 7622. She leads the Radiopharmaceutical Chemistry Research Group, focusing on translational nuclear medicine applications. Her research spans radiopharmaceutical chemistry, PET radiochemistry, image-assisted drug delivery, pretargeted PET imaging, theranostics, and nanotheranostics. Key methodologies include prosthetic group design, bioorthogonal chemistry, and nanocarrier development for precision oncology applications. Current projects target glioblastoma, colorectal cancer, breast cancer, and brain metastasis through innovative radiotracer platforms. Recent publications (2023-2025) reveal strong trends in tumor-targeted nanotheranostics, particularly spherical nucleic acids and pretargeted imaging strategies using trans-cyclooctene/tetrazine systems. Her work bridges radiochemistry and clinical oncology, emphasizing boron neutron capture therapy agents and fatty acid binding protein imaging probes across EJNMMI Radiopharmacy and Chemistry, ACS Omega, and Nuclear Medicine and Biology. Collaborative networks span multidisciplinary teams across oncology, biochemistry, and nanotechnology domains. Her leadership in the Radiopharmaceutical Chemistry Research Group drives advancements in molecular imaging probe design and therapeutic applications, with emphasis on clinical translation of novel radioconjugates.

Jelena M. Janjicمشاهده پروفایل

دانشیار

• Nanomedicine
• Drug Delivery
• Pain Therapeutics
• +۵ مورد دیگر

Jelena M. Janjic is a tenured Associate Professor of Pharmaceutics at Duquesne University's School of Pharmacy and Graduate School of Pharmaceutical Sciences. She holds a PhD in Medicinal Chemistry from the University of Pittsburgh (2005) and a Diplomirani Farmaceut from Belgrade University (1998). Since 2009, she has directed the Nanomedicine Manufacturing Laboratory, focusing on theranostic platforms for inflammatory diseases. Her research integrates nanotechnology, molecular imaging, and drug delivery to address chronic pain, inflammation, and transplant medicine. Key innovations include macrophage-targeted nanoemulsions for neuropathic pain, perfluorocarbon-based oxygen carriers for regenerative medicine, and quality-by-design manufacturing of nanotherapeutics. She founded the Chronic Pain Research Consortium, securing over $6M in external funding from DoD/CDMRP, NIH, and USAF for interdisciplinary pain research. Publications emphasize sex differences in pain response, macrophage biology in neuropathy, and translational nanomedicine for combat casualty care. Recent work explores diabetic neuropathy mechanisms, ferroptosis inhibition, and non-invasive graft monitoring using multimodal imaging. Awards & Recognition: Dean’s Award (2023) President’s Award of Excellence (2020) Carnegie Science Award (2020) Defense Tech Connect Innovator (2019) Pittsburgh Business Times Innovator (2018) Research Hall of Fame Inductee (2018) Research Leadership: She directs multiple DoD contracts including neuroimmune-modulating analgesics for diabetic neuropathy ($4.2M) and oxygen-carrying nanoemulsions for trauma resuscitation. Mentors PhD/MS/PharmD students in nanomedicine formulation, in vivo evaluation, and manufacturing scale-up. Laboratory: The Nanomedicine Manufacturing Laboratory (2,094 sq ft) specializes in GMP-like production of theranostic agents, featuring microfluidizers, analytical HPLC, and preclinical imaging capabilities. Current projects include combat casualty care solutions for the US Air Force.

Kit Lamمشاهده پروفایل

استاد

• Combinatorial Chemistry
• Drug Development
• Nanotheranostics
• +۳ مورد دیگر

Dr. Kit Lam is Professor of Biochemistry and Molecular Medicine at UC Davis, renowned for pioneering combinatorial chemistry and one-bead-one-compound (OBOC) drug discovery technology. His lab develops cancer-targeted nanotherapeutics, molecular imaging agents, and peptide-based diagnostics. Research spans combinatorial library synthesis, cancer nanomedicine, molecular immunology, and antibiotic development. Recent innovations include PLZ4-targeted micelles for bladder cancer, apolipoprotein nanodiscs, and vision transformer-based drug screening. Collaborations extend to veterinary oncology for clinical translations. Awards include Immunomedics Science Award and American Chemical Society Fellowship. His 1991 OBOC patent revolutionized high-throughput drug screening.

• Drug Delivery Systems
• Nanoparticles
• Quality by Design (QbD)
• +۳ مورد دیگر

Sandeep Kumar Singh is a Senior Lecturer and Program Director (Pharmaceutical Sciences) at the University of Technology Sydney's School of Mathematical and Physical Sciences. His research focuses on advanced drug delivery systems using nanoparticles, including lipid-based formulations and self-nanoemulsifying systems, with an emphasis on Quality by Design (QbD) principles. He employs in silico tools like GastroPlus® to predict drug behavior and enhance formulation robustness. Education: PhD from Birla Institute of Technology (Mesra), M.Pharm from Panjab University, and postdoctoral research at Pukyong National University (South Korea). Research Projects: Completed two projects on lipid-based systems for tuberculosis treatment. Teaching: Principles of Pharmaceutical Sciences and Cosmetics/Neutraceuticals modules. His work addresses bioavailability challenges through nanotechnology, with applications in cardiovascular, oncology, and infectious disease therapies. Over 70 students (undergraduate, postgraduate, and PhD) have been advised under his supervision.

Yaowu Haoمشاهده پروفایل

استاد

• Nanomedicine
• Nanotechnology
• Nuclear Medicine
• +۷ مورد دیگر

Dr. Yaowu Hao is a Professor in the Department of Materials Science and Engineering at the University of Texas at Arlington. He holds joint appointments in both Materials Science and Engineering and Bioengineering departments. His academic journey began with a BS and MS in Metal Physics and Chemistry from the University of Science and Technology in Beijing, followed by an MS in Materials Science and Engineering from the University of Florida, and culminated with a PhD in Materials Science and Engineering from MIT in 2003. After completing a postdoctoral fellowship at Johns Hopkins University, he joined UT Arlington in 2005, progressing from Assistant Professor to Associate Professor and ultimately to his current position as Professor since 2018. Dr. Hao's research focuses primarily on nanomedicine, with specific interests in plasmonic metal and semiconductor nanoparticles for biomedical imaging and drug delivery applications, as well as radioactive copper-based inorganic nanoparticles for biomedical imaging and therapeutic applications. His work spans nanotechnology, nuclear medicine, plasmonics, and magnetic materials, with a strong emphasis on developing novel nanomaterials for cancer diagnosis and treatment. His laboratory has made significant contributions to the fields of hollow nanoparticles, surface-enhanced Raman scattering (SERS) substrates, and nanotheranostic agents. Analysis of Dr. Hao's recent publications reveals a consistent focus on nanomaterial synthesis and biomedical applications. His work demonstrates expertise in creating various nanostructures (gold, silver, tungsten disulfide) with specific morphologies for targeted applications, particularly in cancer therapy and diagnostics. There's a clear progression from fundamental nanomaterial synthesis to increasingly sophisticated theranostic applications, with recent work focusing on radiolabeling strategies, improved memory devices, and advanced SERS substrates for sensitive detection. US patent 9,040,157: Hollow nanoparticles and nanocomposites and methods of making hollow nanoparticles and nanocomposites (issued May 26, 2015) US patent 9,801,962 B2: Radioactive nanoparticles and methods and using of the same (issued October 31, 2017) Dr. Hao has mentored numerous graduate students through their PhD and MS research projects, with current advisees including Christopher Pickering, Aseem Athavale, Shahab Ranjbar Bahadori, and Ryan Hart. His research has been generously supported by multiple federal grants from NIH and NSF, as well as state funding from organizations like the Cancer Prevention & Research Institute of Texas. Current major projects include "Radiotherapeutic Nanoseeds for Internal Radiation Therapy of Unresectable Solid Tumors" (NIH-funded) and "Collaborative Research: Hollow Nanoparticle Synthesis" (NSF-funded). Dr. Hao leads the Hao Research Group, which focuses on developing novel nanomaterials for biomedical applications. The group maintains strong collaborations with researchers in bioengineering and oncology, particularly in developing nanotheranostic agents for cancer treatment. Current projects involve radioactive nanoseeds for glioblastoma treatment, renal clearable nanoparticles, and advanced SERS substrates for sensitive molecular detection.

Nanasaheb Thoratمشاهده پروفایل

دانشیار

• Nanomedicine
• Cancer Therapy
• Magnetic Nanoparticles
• +۷ مورد دیگر

Nanasaheb Thorat is an Associate Professor at the University of Limerick, affiliated with the Department of Physics, Bernal Institute, and Limerick Digital Cancer Research Centre. His research focuses on nanomedicine, cancer therapy, magnetic nanoparticles, and exosome-based applications. He is actively involved in developing advanced drug delivery systems, cancer imaging techniques, and nanotheranostics. His work integrates materials science, biomedical engineering, and oncology to address challenges in cancer treatment and diagnosis. Research interests include magnetic nanoparticle synthesis for hyperthermia, exosome engineering for targeted therapies, and the development of smart nanomaterials for drug delivery. He has contributed to advancements in photothermal therapy, cancer biomarker discovery, and the use of PROTACs for viral infections. His interdisciplinary approach bridges physics, chemistry, and medicine, with a strong emphasis on translating nanotechnology into clinical applications. Thorat’s recent work highlights trends in 3D tumor models for drug screening, AI-driven cancer diagnostics, and the clinical potential of nanovaccines. He collaborates globally on projects related to cancer nanomedicine, magnetic hyperthermia, and exosome-based diagnostics. His research aligns with UN Sustainable Development Goals targeting health and well-being through innovative biomedical solutions. He is open to supervising PhD students in areas such as nanomedicine, cancer therapeutics, and biomaterials. His contributions to the field are evident in over 116 peer-reviewed publications, emphasizing the application of nanotechnology in healthcare and biomedical innovation.

Carolina de Aguiar Ferreiraمشاهده پروفایل

استادیار

• Cancer Theranostics
• Radiopharmaceuticals
• Nanomedicine
• +۳ مورد دیگر

Carolina de Aguiar Ferreira, PhD, is an Assistant Professor in Radiology, Pharmacology & Toxicology at Michigan State University's College of Osteopathic Medicine. Her research focuses on developing advanced radiopharmaceuticals, nanomedicines, and theranostic systems for cancer diagnosis and treatment. Key areas include targeted drug delivery, molecular imaging (e.g., PET), and optimizing radiation therapies' immunomodulatory effects. Her work emphasizes translational applications such as: Radiolabeled peptides and antibodies for tumor targeting Ultrasensitive imaging probes for disease activity (e.g., inflammatory bowel disease, fibrosis) Nanoparticle platforms for enhanced pharmacokinetics and reduced toxicity Notable contributions include: Developing Y-86/90-labeled antibodies for pancreatic cancer theranostics Pioneering Granzyme B PET imaging for non-invasive disease monitoring Engineering cerenkov radiation-amplified nanotheranostics Her lab investigates synergies between radioimmunotherapy and immunotherapy, with recent studies exploring alpha-particle emitting radionuclides (e.g., 225Ac) to enhance antitumor immunity. She also designs renal-accumulating nanomaterials for acute kidney injury management. Dr. Ferreira’s work bridges radiology, pharmacology, and biomedical engineering, with 100+ peer-reviewed articles and multiple patents pending. She collaborates with clinical teams to advance precision oncology and diagnostic imaging technologies.